These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6235162)

  • 1. [Mongolism following omitted amniocentesis].
    Fortschr Med; 1984 Feb; 102(8):68. PubMed ID: 6235162
    [No Abstract]   [Full Text] [Related]  

  • 2. Malpractice and women 35 years of age or more at delivery.
    Hecht F; Hecht BK
    Ariz Med; 1982 Dec; 39(12):785-7. PubMed ID: 6218798
    [No Abstract]   [Full Text] [Related]  

  • 3. Eligibility criteria for amniocentesis.
    Vekemans M; Lippman A
    Am J Med Genet; 1984 Feb; 17(2):531-3. PubMed ID: 6230936
    [No Abstract]   [Full Text] [Related]  

  • 4. Method of risk assessment affects acceptance rate of amniocentesis.
    de la Vega A; Verdiales M; Leavitt G
    P R Health Sci J; 2002 Sep; 21(3):233-5. PubMed ID: 12243114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down syndrome prevention program in a population with an older maternal age.
    Shohat M; Legum C; Romem Y; Borochowitz Z; Bach G; Goldman B
    Obstet Gynecol; 1995 Mar; 85(3):368-73. PubMed ID: 7862374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic screening: some of the issues.
    Soskis CW
    Health Law Proj Libr Bull; 1980 Jan; 5(1):1-8. PubMed ID: 10313635
    [No Abstract]   [Full Text] [Related]  

  • 7. [Technic, indications and risks in genetic amniocentesis during early pregnancy].
    Husslein P; Wagenbichler P
    Wien Med Wochenschr; 1980 Jan; 130(2):93-5. PubMed ID: 6446206
    [No Abstract]   [Full Text] [Related]  

  • 8. [Controversy: systemic amniocentesis for women 38 years and more? Is it not premature to no longer accept performing amniocentesis on a patient age 38 years or more?].
    Sagot P
    Gynecol Obstet Fertil; 2000 Oct; 28(10):769-71. PubMed ID: 11270348
    [No Abstract]   [Full Text] [Related]  

  • 9. [The new biotechnology law and the old maternal age criterium].
    Solberg B
    Tidsskr Nor Laegeforen; 2003 Oct; 123(19):2741-3. PubMed ID: 14600751
    [No Abstract]   [Full Text] [Related]  

  • 10. Mongolism preventable by amniocentesis. An appraisal of the genetic considerations.
    Bodensteiner JB; Zellweger H
    Clin Pediatr (Phila); 1971 Oct; 10(10):554-6. PubMed ID: 4257023
    [No Abstract]   [Full Text] [Related]  

  • 11. [Screening for Down's syndrome in the 2d trimester of pregnancy: initial results].
    Stejskal D
    Cesk Gynekol; 1993 Feb; 58(1):5-10. PubMed ID: 8319282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidemiology of Down syndrome in Spain. I. Maternal age: application of the results in primary prevention health programs].
    Martínez Frias ML; Salvador Peral J
    Rev Sanid Hig Publica (Madr); 1985; 59(3-4):325-35. PubMed ID: 2934795
    [No Abstract]   [Full Text] [Related]  

  • 13. [Blood screening for Down's syndrome in women under 35 years of age with an age-independent index].
    Benz R; Müller U; Krahner-Pilat M; Wagner-Geuder S; Terinde R
    Z Geburtshilfe Perinatol; 1993; 197(5):205-8. PubMed ID: 7505992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Down syndrome: the Jerusalem experience.
    Bach G; Ben-Neriah Z; Sagi M
    Isr J Med Sci; 1993 Aug; 29(8):468-70. PubMed ID: 7691779
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Down's syndrome. Data do not support study's claim.
    Norgaard-Pedersen B
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999925
    [No Abstract]   [Full Text] [Related]  

  • 17. Down syndrome screening in Singapore--the effectiveness of a second trimester serum screening policy modelled on 29,360 pregnancies in KK Women's and Children's Hospital.
    Lai FM; Yeo GS
    Singapore Med J; 1998 Feb; 39(2):69-75. PubMed ID: 9652180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of trisomy 21 risk by serial determination of chorionic gonadotrophin hormone and alpha-fetoprotein: results of a national pilot study].
    Aymé S; Aurran Y; Chabal F; Gombert A; Loundou H; Montfort C; Sollier M; Silvestri A
    Contracept Fertil Sex; 1993 Feb; 21(2):133-43. PubMed ID: 7524931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [When the admitting physician is accused of a false decision in the hospital... Guiding decision for amniocentesis--some flaws].
    Waibl K; Bayer M
    Fortschr Med; 1989 Jul; 107(20):64-5. PubMed ID: 2527796
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comment on the contribution by Benz et al.: Serum screening for Down syndrome in women under 35 years of age with an age independent index].
    Reynolds T; Pistorius K; Spencer K; John R
    Z Geburtshilfe Neonatol; 1995; 199(3):128-9. PubMed ID: 7553259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.